SLC5A2 and Stroke: While able to reduce hospitalization for heart failure, kidney disease progression and cardiovascular death, sodium–glucose linked cotransporter-2 (SGLT2) inhibitors are not generally regarded as agents that reduce the atherosclerotic components of MACE: myocardial infarction and stroke.